A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting Beta2 Agonist in Patients With Uncontrolled Asthma

Trial Profile

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting Beta2 Agonist in Patients With Uncontrolled Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SIROCCO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Mar 2018 Results of a post-hoc analysis assessing Changes in Morning Peak Expiratory Flow in patients from SIROCCO and CALIMA trials, presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 05 Mar 2018 Results (n=122) of subanalysis evaluated benralizumab for patients from the Republic of Korea in SIROCCO, were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Mar 2018 Results of pooled analysis of phase III SIROCCO and CALIMA assessing seasonal variability of exacerbations in patients with severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab, were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top